Genomic Profiling and Liquid Biopsies for Breast Cancer.

Autor:	Marcinak CT; Department of Surgery, University of Wisconsin-Madison, Madison, WI, USA; Center for Human Genomics and Precision Medicine, University of Wisconsin-Madison, Madison, WI, USA. Electronic address: https://twitter.com/ctmarcinak., Murtaza M; Department of Surgery, University of Wisconsin-Madison, Madison, WI, USA; Center for Human Genomics and Precision Medicine, University of Wisconsin-Madison, Madison, WI, USA., Wilke LG; Department of Surgery, University of Wisconsin-Madison, Madison, WI, USA; University of Wisconsin Carbone Cancer Center, Madison, WI, USA. Electronic address: wilke@surgery.wisc.edu.
Jazyk:	angličtina
Zdroj:	The Surgical clinics of North America [Surg Clin North Am] 2023 Feb; Vol. 103 (1), pp. 49-61. Date of Electronic Publication: 2022 Oct 17.
DOI:	10.1016/j.suc.2022.08.003
Abstrakt:	The cancer genome plays an increasingly large role in the care of patients with breast cancer. Commercially available gene-expression profiling assays are now a part of staging and treatment guidelines, and their use continues to be examined in large-scale studies. With the advent of next-generation sequencing, the cancer genome can now be examined more quickly, less invasively, and in much greater detail. These technologies have led to a more nuanced understanding of molecular pathways, allowing providers to better match patients to clinical trials. Furthermore, a new era of diagnostics based on liquid biopsies is expected to revolutionize disease detection and clinical care. (Copyright © 2022 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu